Details of the Drug Combination

General Information of Drug Combination (ID: DCIOVOY)

• Drug Combination Name: LY03004 + Acarbose
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  LY03004 (DME5TUR): N.A.
  Acarbose (DMRM3AW): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 24.16
  Bliss Independence Score: 24.16
  Loewe Additivity Score: 38.65
  LHighest Single Agent (HSA) Score: 38.67

Molecular Interaction Atlas of This Drug Combination

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[2]

Indication(s) of Acarbose

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[3]
Non-insulin dependent diabetes	5A11	Approved	[4]
Cardiovascular disease	BA00-BE2Z	Phase 3	[3]

Acarbose Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Modulator	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6791).
• [4] Acarbose FDA Label
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.